While SPARC promoter methylation is a frequent event in several cancers and may contribute to ECM dysregulation in both fibrotic and malignant settings, the extent to which this epigenetic mark confers increased cancer susceptibility in IPF remains unclear. The gene discussed is SPARC; the disease is cancer.